The clients who arrive at Holina with a benzodiazepine problem rarely think of it that way at first. They began with a doctor’s prescription, written for sleep or anxiety or panic, often after a clearly difficult period in their life. The medication worked, in the short term, in the way it was designed to. And then, somewhere across the following months or years, the relationship to the medication quietly shifted. The dose required for the same effect rose. Missing a day produced a symptom worse than the one the medication was originally treating. The line between treatment and dependence became, for them, invisible.

This is the most common presentation of benzodiazepine dependence we see, and it is also one of the most clinically delicate. Benzodiazepines are unlike most substances in addiction medicine: the withdrawal from chronic use is genuinely dangerous, the timeline of safe discontinuation is long, and the most commonly available detox protocols, even at credible facilities, are frequently calibrated to a faster schedule than the medication allows. This piece is for clients and families trying to understand why the slow taper matters, and what it looks like done well.

What Benzodiazepine Dependence Actually Is

The benzodiazepine picture has shifted markedly. US CDC analysis documents that benzodiazepine prescribing rates have increased substantially over the past two decades, with overdose deaths involving benzodiazepines rising more than tenfold since 1999. The Ashton Manual remains the most widely-referenced clinical guide for the slow-taper approach.

Benzodiazepines — Xanax, Valium, Klonopin, Ativan, Lorazepam, Temazepam, and several others — work by enhancing the activity of GABA, the brain’s primary inhibitory neurotransmitter. The effect is calming, and in the right contexts, genuinely useful for short-term management of acute anxiety, panic, sleep disturbance, and certain seizure disorders. The trouble begins with sustained use. Within weeks to months, the brain adjusts its own GABA system in response to the additional input, reducing its native production and altering receptor sensitivity. By the time someone has been on a benzodiazepine for six months continuously, the underlying neurochemistry has changed.

What this means in practice is that the person is no longer in the same body that began the medication. Stopping abruptly does not return the system to its pre-medication baseline. It exposes the now-adjusted system to its own undermedicated state, and the resulting withdrawal is what makes benzodiazepine cessation clinically distinctive.

Why Benzodiazepine Withdrawal Is Different

Most addiction withdrawal, while uncomfortable, is not medically dangerous in adults without other significant health conditions. Alcohol withdrawal at the severe end is, alongside benzodiazepine withdrawal, the exception. Stopping a chronic benzodiazepine suddenly can produce seizures, severe autonomic instability, prolonged insomnia, panic states that meaningfully exceed the original anxiety, and a constellation of neurological symptoms — visual disturbances, tinnitus, derealisation, muscle rigidity — that can persist for weeks or months.

The phenomenon is well-documented in the clinical literature and goes by several names: protracted withdrawal, post-acute withdrawal syndrome from benzodiazepines, or in the patient communities that have organised around it, the Ashton Protocol, after the British psychiatrist Heather Ashton who developed the most widely-referenced tapering schedule.

The central clinical insight is that the brain’s GABA system takes far longer to recalibrate than the medication takes to leave the body. The half-life of most benzodiazepines is days at most. The recovery of native GABA function can take many months. A taper that is faster than this recovery curve produces sustained withdrawal symptoms; a taper that respects it allows the system to adjust at the pace it can actually manage.

Why Most Detoxes Get the Timing Wrong

Standard residential detox protocols at most facilities are built around alcohol and opioid presentations, where the acute medical withdrawal is shorter and the residential window can encompass it. For alcohol, a detox of five to ten days is generally clinically adequate. For opioids, seven to fourteen. Benzodiazepine detox, when done at the speed the medication actually warrants, can take six weeks to several months.

This is, simply, longer than the standard 28-day residential window. The result, at many facilities, is one of three patterns. Some facilities do a faster taper than the medication warrants, producing withdrawal symptoms that the client misattributes to underlying anxiety and that often drive return to use after discharge. Some facilities decline benzodiazepine admissions altogether, referring the client elsewhere. Some facilities take the client on, do the early stabilisation well, and then discharge before the taper is anywhere near complete, expecting outpatient continuation that frequently does not happen.

None of these patterns is malicious. They are, in most cases, the consequence of trying to fit a benzodiazepine presentation into a treatment structure that was not designed for it.

What the Slow Taper Actually Looks Like

A well-conducted benzodiazepine taper typically begins with a cross-titration onto a longer-acting benzodiazepine, most commonly diazepam, which is then reduced in small, evenly-spaced decrements over an extended schedule. The decrement size and the spacing between reductions depend on the original dose, the duration of use, the client’s response to early reductions, and the presence of any complicating conditions.

A reasonable taper for a client who has been on a moderate dose of a short-acting benzodiazepine for several years might look like a five to ten percent reduction every two to three weeks, with longer holds when symptoms emerge and resumption only once stability returns. This is not a fast process. It is, in clinical terms, the process the medication actually requires.

What makes the work possible in a residential setting is the surrounding support — sleep architecture restoration, nutritional support, somatic and nervous system regulation work, the gentle treatment of the underlying anxiety or trauma that the medication was originally prescribed for, and the continuous clinical attention that allows decrements to be adjusted in real time rather than according to a fixed schedule.

The Underlying Condition Almost Always Matters

Benzodiazepine dependence is rarely the whole picture. The original prescription was, in most cases, for something — panic disorder, generalised anxiety, complex trauma, treatment-resistant insomnia. The medication has been suppressing the surface symptoms of that condition for years, in some cases. As the taper progresses, the underlying condition often resurfaces, sometimes in forms the client has not consciously felt in a long time.

This is a clinical opportunity, not a complication. The work that the medication was substituting for can finally be done. Trauma processing, where indicated, can address the substrate of the original anxiety. Somatic and nervous-system-focused therapies can begin to do, in months, what the medication has been doing chemically for years. Where the underlying condition is well-treated during the taper, the post-taper outcome is meaningfully better than where the taper is conducted as a chemistry problem alone.

This is the principal reason that benzodiazepine work belongs in a setting that integrates medical detox with deeper psychotherapeutic and somatic care, rather than in a setting that is purely a medical detox unit.

What a Realistic Holina Admission Looks Like

For benzodiazepine presentations specifically, we typically recommend longer admissions than for alcohol or stimulant presentations. A 60-day residential program is the minimum for moderate dependence on shorter-acting benzodiazepines; 90 days is appropriate for longer-duration use, higher doses, or polysubstance presentations involving benzodiazepines alongside alcohol or opioids. In some cases, a residential program is followed by an extended outpatient or sober-living taper continuation, which may add several months to the total work.

This is not a length families typically arrive expecting. It is, however, the length the medication itself requires for a taper that is both safe and sustainable. We have, in our experience, met fewer benzodiazepine clients who regretted the longer admission than we have met who regretted the shorter one. The taper that is rushed almost always returns. The taper that is given its time generally does not.

A Closing Note for Clients Currently on Benzodiazepines

If you are reading this and recognising your own pattern, the most important thing to know is that the issue is not a moral failure. Benzodiazepine dependence is, in most cases, the chemical consequence of taking a working medication for longer than it was designed to be taken. The dependence is real, and so is the discomfort of coming off. Neither is shameful, and both are addressable in a setting calibrated to the actual demands of the work.

Do not stop your medication abruptly. Do not attempt a fast taper without clinical supervision. The benzodiazepine withdrawal that is mismanaged becomes, in some cases, the trauma that the next decade of recovery work has to address. The benzodiazepine withdrawal that is managed well becomes a finite, contained, demanding piece of work that ends — and beyond which a meaningfully different life is available.

Holina’s clinical team will speak with you and your prescribing physician about a path that fits your specific medication, dose, and history. The first call is the beginning of the planning, not the beginning of the taper itself.

— Ian Young

Related Reading

• 30 60 90 Day Rehab Length Family Guide
• Sleep Circadian Rhythm Clinical Intervention
• Sex Love Addiction Attachment Trauma Compulsive Behavior